These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 37844322)

  • 1. Real-world impact of infliximab precision-guided dosing on management of patients with IBD.
    Abraham BP; Ziring DA; Dervieux T; Han PA; Shim A; Battat R
    Am J Manag Care; 2023 Oct; 29(12 Suppl):S227-S235. PubMed ID: 37844322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dashboard-Driven Accelerated Infliximab Induction Dosing Increases Infliximab Durability and Reduces Immunogenicity.
    Dubinsky MC; Mendiolaza ML; Phan BL; Moran HR; Tse SS; Mould DR
    Inflamm Bowel Dis; 2022 Sep; 28(9):1375-1385. PubMed ID: 34978325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Forecasted infliximab concentrations during induction predict time to remission and sustained disease control of inflammatory bowel disease.
    Vermeire S; Dubinsky MC; Rabizadeh S; Panetta JC; Spencer EA; Dreesen E; D'Haens G; Dervieux T; Laharie D
    Clin Res Hepatol Gastroenterol; 2024 Jun; 48(6):102374. PubMed ID: 38750934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of Infliximab Trough Concentrations in Inflammatory Bowel Disease Patients Using a Repeated-Measures Design.
    Santacana E; Rodríguez-Alonso L; Padullés A; Guardiola J; Bas J; Rodríguez-Moranta F; Serra K; Morandeira F; Colom H; Padullés N
    Ther Drug Monit; 2020 Feb; 42(1):102-110. PubMed ID: 31283556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of dashboard driven dosing of infliximab in inflammatory bowel disease patients; a randomized controlled trial.
    Strik AS; Löwenberg M; Mould DR; Berends SE; Ponsioen CI; van den Brande JMH; Jansen JM; Hoekman DR; Brandse JF; Duijvestein M; Gecse KB; de Vries A; Mathôt RA; D'Haens GR
    Scand J Gastroenterol; 2021 Feb; 56(2):145-154. PubMed ID: 33290108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic Dashboard-Recommended Dosing Is Different than Standard of Care Dosing in Infliximab-Treated Pediatric IBD Patients.
    Dubinsky MC; Phan BL; Singh N; Rabizadeh S; Mould DR
    AAPS J; 2017 Jan; 19(1):215-222. PubMed ID: 27739008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infliximab Therapeutic Drug Monitoring Changes Clinical Decisions in a Virtual Biologics Clinic for Inflammatory Bowel Disease.
    Selinger CP; Lenti MV; Clark T; Rafferty H; Gracie D; Ford AC; OʼConnor A; Ahmad T; Hamlin PJ
    Inflamm Bowel Dis; 2017 Dec; 23(12):2083-2088. PubMed ID: 29140939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of Hydrocortisone Premedication Discontinuation in Patients with Inflammatory Bowel Disease on Maintenance Therapy with Infliximab: a Prospective Clinical and Pharmacological Study.
    Tran-Minh ML; Gornet JM; Maillet M; Houze P; Simon M; McLellan P; Hassid D; Vivier-Chicoteau J; Baudry C; Hammoudi N; Allez M
    J Crohns Colitis; 2021 May; 15(5):742-748. PubMed ID: 33205193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics of infliximab in patients with inflammatory bowel disease: potential implications for dosing in clinical practice.
    Buurman DJ; Maurer JM; Keizer RJ; Kosterink JG; Dijkstra G
    Aliment Pharmacol Ther; 2015 Sep; 42(5):529-39. PubMed ID: 26113313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Mobile Infliximab Dosing Calculator for Therapy Optimization in Inflammatory Bowel Disease.
    Piester T; Frymoyer A; Christofferson M; Yu H; Bass D; Park KT
    Inflamm Bowel Dis; 2018 Jan; 24(2):227-234. PubMed ID: 29361094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dried blood samples can support monitoring of infliximab concentrations in patients with inflammatory bowel disease: A clinical validation.
    Berends SE; D'Haens GRAM; Schaap T; de Vries A; Rispens T; Bloem K; Mathôt RAA
    Br J Clin Pharmacol; 2019 Jul; 85(7):1544-1551. PubMed ID: 30927375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved Population Pharmacokinetic Model for Predicting Optimized Infliximab Exposure in Pediatric Inflammatory Bowel Disease.
    Bauman LE; Xiong Y; Mizuno T; Minar P; Fukuda T; Dong M; Rosen MJ; Vinks AA
    Inflamm Bowel Dis; 2020 Feb; 26(3):429-439. PubMed ID: 31287855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infliximab in young paediatric IBD patients: it is all about the dosing.
    Jongsma MME; Winter DA; Huynh HQ; Norsa L; Hussey S; Kolho KL; Bronsky J; Assa A; Cohen S; Lev-Tzion R; Van Biervliet S; Rizopoulos D; de Meij TGJ; Shouval DS; Wine E; Wolters VM; Martinez-Vinson C; de Ridder L;
    Eur J Pediatr; 2020 Dec; 179(12):1935-1944. PubMed ID: 32813123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Model Informed Precision Dosing Tool Forecasts Trough Infliximab and Associates with Disease Status and Tumor Necrosis Factor-Alpha Levels of Inflammatory Bowel Diseases.
    Primas C; Reinisch W; Panetta JC; Eser A; Mould DR; Dervieux T
    J Clin Med; 2022 Jun; 11(12):. PubMed ID: 35743387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dosing interval and diagnosis predict infliximab levels in patients with inflammatory bowel disease on maintenance treatment.
    Krajcovicova A; Batovsky M; Gregus M; Hlista M; Durina J; Leskova Z; Sturdik I; Gojdic M; Jalali Y; Koller T; Toth J; Huorka M; Hlavaty T
    Acta Gastroenterol Belg; 2018; 81(4):465-470. PubMed ID: 30645913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors associated with reduced infliximab exposure in the treatment of pediatric autoimmune disorders: a cross-sectional prospective convenience sampling study.
    Funk RS; Shakhnovich V; Cho YK; Polireddy K; Jausurawong T; Gress K; Becker ML
    Pediatr Rheumatol Online J; 2021 May; 19(1):62. PubMed ID: 33933127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infliximab Trough Levels Are Not Predictive of Relapse in Patients with IBD in Endoscopic Remission: A Multicenter Cohort Study.
    Borren NZ; Paulides E; Frinack JL; Olson RN; Willrich MAV; van der Woude CJ; Ananthakrishnan AN
    Dig Dis Sci; 2021 Oct; 66(10):3548-3554. PubMed ID: 33037969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infliximab in paediatric inflammatory bowel disease: External evaluation of population pharmacokinetic models.
    Heikal OS; van Rheenen PF; Touw DJ; Kosterink JGW; Maurer M; Koomen JV; Chelle P; Mian P
    Br J Clin Pharmacol; 2024 Sep; 90(9):2200-2214. PubMed ID: 38845210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the Quantum Blue® reader Point-of-Care system versus ELISA technique for therapeutic drug monitoring of Infliximab levels.
    Novakovic V; Abdija S; Larsen PB; Fenger M; Gredal L; Jacobsen KK
    Clin Biochem; 2019 Dec; 74():73-75. PubMed ID: 31669514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Utility of Infliximab Therapeutic Drug Monitoring among Patients with Inflammatory Bowel Disease and Concerns for Loss of Response: A Retrospective Analysis of a Real-World Experience.
    Mitchell RA; Shuster C; Shahidi N; Galorport C; DeMarco ML; Rosenfeld G; Enns RA; Bressler B
    Can J Gastroenterol Hepatol; 2016; 2016():5203898. PubMed ID: 27957480
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.